Arphra
live
S&P 5000.30
NASDAQ0.00
DOW49,602.49
VIX18.06
US10Y4.47
EUR/USD1.1535
GOLD4,255.9
WTI89.00
BTC61,608.42
S&P 5000.30
NASDAQ0.00
DOW49,602.49
VIX18.06
US10Y4.47
EUR/USD1.1535
GOLD4,255.9
WTI89.00
BTC61,608.42

ZYDUSLIFE.BO

Zydus Lifesciences Limited
HealthcareDrug Manufacturers - Specialty & GenericININRPeers →Country macro →
$1,088.90
Jun 05, 2026
AI Brief
Market cap
$1.1T
52w range
P / E
EPS · FY 2026
$50.09
Volume
Revenue · FY 2026
$271.48B
+16.81% YoY

Explain this page

Arphra AI
Business description
· company · SEC profile

Zydus Lifesciences Limited

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India.

Founded
IPO
Jul 01, 2002
Employees
26,921
HQ
Ahmedabad
CEO
Punit Patel
CFO
Exchange
BSE
Fiscal year
Identifiers
· company_identifiers
CIK
CUSIP
ISININE010B01027
FIGIZYDUSLIFE IB
LEI